HOME >> BIOLOGY >> NEWS
On life support: Future of science focus of lecture at UH

HOUSTON, Nov. 9, 2006 Former presidential adviser for science and technology policy, Neal Lane, is coming to the University of Houston to address the uncertain future of science in the United States.

As part of the annual UH Tenneco Distinguished Lecture Series, Lane, who also is the former director of the National Science Foundation, will speak in the main auditorium of the UH Science and Engineering Research and Classroom Complex at 5 p.m., Tuesday, Nov. 28. The lecture is free and open to the public.

In his talk, "U.S. Science Glorious Past, Uncertain Future," Lane will address three issues that will directly affect science: money, people and public understanding. He also will touch on three areas that he believes U.S. science and technology policy is in disarray: health and medical research; energy and environment; and space science and exploration. The lecture will conclude with thoughts about what might be done to address these concerns.

"The United States has enjoyed six decades of extraordinary scientific advancement made possible, in part, by enlightened policies to support basic research and encourage the use of new scientific knowledge and technologies to benefit the American people," Lane said. "But America indeed the world is in a very different state than it was at the end of World War II. The future of U.S. science is uncertain, and many of its vital signs are not good."

Widely regarded as a distinguished scientist and educator, Lane has written and presented extensively on topics that include theoretical, atomic and molecular physics and science and technology policy. He is the Malcolm Gillis University Professor at Rice University. He also holds appointments as a senior fellow of the James A. Baker III Institute for Public Policy, where he is engaged in science and technology policy, and in the Department of Physics and Astronomy.

Lane served in the federal government from 1998 to
'"/>

Contact: Lisa Merkl
lkmerkl@uh.edu
713-743-8192
University of Houston
9-Nov-2006


Page: 1 2

Related biology news :

1. Keck Futures Initiative announces grant recipients
2. The Origin, Evolution, and Future of Life on Earth
3. The Future of Chemical Plant Security one-day symposium, Monday, Aug. 29
4. National Academies Keck Futures Initiative to co-sponsor life engineering symposium
5. Future diabetes drugs may target new protein interaction
6. Future Vision 2005 to feature innovation in endoscopy
7. AFCYBER holds science and technology symposium
8. News tips from the Journal of Neuroscience
9. Neurosciences and music meet in Montreal
10. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. News tips from the Journal of Neuroscience

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... by 2021 from $8.3 billion in 2016 at a ... to 2021. Report Includes - An overview of ... market trends, with data from 2015 and 2016, and ... - Segmentation of the market on the basis of ...
(Date:2/7/2017)... Feb. 7, 2017 Zimmer Biomet Holdings, Inc. ... healthcare, will present at the LEERINK Partners 6th Annual ... Hotel on Wednesday, February 15, 2017 at 10 a.m. ... the presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  ... conference via Zimmer Biomet,s Investor Relations website at ...
(Date:2/6/2017)... , Feb. 6, 2017 According to ... are driving border authorities to continue to embrace ... there are 2143 Automated Border Control (ABC) eGates ... deployed at more than 163 ports of entry ... to 2016 achieving a combined CAGR of 37%. ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... ... February 24, 2017 , ... Delpor, Inc. (Delpor), a biotechnology company focused ... Institute of Mental Health (NIMH) for the further advancement of the company’s 3-month olanzapine ... and is expected to deliver therapeutic levels of olanzapine for a period of 3 ...
(Date:2/24/2017)... , Feb. 24, 2017 Symic Bio, a ... a new category of therapeutics, announced today the completion ... in peripheral artery disease. The trial will evaluate the ... therapeutic, in the reduction of restenosis following angioplasty. ... development milestone for SB-030," said Nathan Bachtell , ...
(Date:2/24/2017)... 23, 2017 China Biologic Products, Inc. (NASDAQ: CBPO) ... biopharmaceutical company in China, today announced its financial results for ... Fourth Quarter 2016 Financial Highlights ... 21.7% in RMB terms, or increased by 13.6% in USD ... quarter of 2015. Gross profit increased by ...
(Date:2/23/2017)... 23, 2017 ... per share data, unaudited)Three Months Ended December 31,Twelve Months ... $         ...   89026%Aldurazyme Net Product Revenue ... Net Product Revenue  756025%297303(2)%Vimizim Net ...
Breaking Biology Technology:
Cached News: